Hualin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hualin Wang has a total of 258 co-authors. Here are the top co-authors by number of shared publications:
- Zhihong Hu
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences
26 shared publications Fei Deng
State Key Laboratory of Virology and Biosafety Wuhan Institute of Virology Chinese Academy of Sciences Wuhan China
25 shared publications- Fei Deng
Key Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
23 shared publications - Yun-Jia Ning
State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
16 shared publications Manli Wang
State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China
15 shared publicationsKuan Feng
State Key Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
12 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (39) , e11575
Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems
Marburg virus (MARV) causes Marburg virus disease (MVD), a severe hemorrhagic fever associated with high morbidity and mortality. No specific antiviral therapies are currently approved for MVD, and viral pathogenesis, particularly the viral pathogenic factor(s) involved, remains poorly defined. Here, we demonstrated that MARV glycoprotein (GP) can induce rounding and detachment of adherent cells, likely by shielding and downregulating cell surface molecules, mainly via its mucin‐like domain (MLD), disrupting monolayer barrier function. In an ex vivo rat vascular model, GP expression caused significant endothelial cell damage and increased vascular permeability. In vivo, MARV GP increases vascular permeability and exacerbates inflammation and tissue injury in mouse muscle and liver transduction models, validating its pathogenic activity. Deletion of the MLD largely abolished these pathogenic effects, indicating its significant role in MARV GP pathogenicity. In addition, using the ex vivo vascular model, we demonstrated the infectivity and pathogenicity of the authentic Ebola virus in vessels and validated the utility of this model as a tool for intervention research against filovirus infection and GP pathogenicity. This study uncovered the remarkable role of MARV GP as a hemorrhage‐related pathogenic factor through multimodal analyses, which may help advance our understanding of viral pathogenesis and lay a foundation for future therapeutic strategies.
- 24 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (39) , e11575
Open AccessMarburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems
Marburg virus (MARV) causes Marburg virus disease (MVD), a severe hemorrhagic fever associated with high morbidity and mortality. No specific antiviral therapies are currently approved for MVD, and viral pathogenesis, particularly the viral pathogenic factor(s) involved, remains poorly defined. Here, we demonstrated that MARV glycoprotein (GP) can induce rounding and detachment of adherent cells, likely by shielding and downregulating cell surface molecules, mainly via its mucin‐like domain (MLD), disrupting monolayer barrier function. In an ex vivo rat vascular model, GP expression caused significant endothelial cell damage and increased vascular permeability. In vivo, MARV GP increases vascular permeability and exacerbates inflammation and tissue injury in mouse muscle and liver transduction models, validating its pathogenic activity. Deletion of the MLD largely abolished these pathogenic effects, indicating its significant role in MARV GP pathogenicity. In addition, using the ex vivo vascular model, we demonstrated the infectivity and pathogenicity of the authentic Ebola virus in vessels and validated the utility of this model as a tool for intervention research against filovirus infection and GP pathogenicity. This study uncovered the remarkable role of MARV GP as a hemorrhage‐related pathogenic factor through multimodal analyses, which may help advance our understanding of viral pathogenesis and lay a foundation for future therapeutic strategies.
- Open Access
- 26 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Interferon-stimulated gene screening identifies CCND3 as a host restriction factor against emerging high-pathogenic bandaviruses
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a representative high-pathogenic bandavirus (Bandavirus genus, Phenuiviridae family). Inducible expression of interferon-stimulated genes (ISGs) is the foundation of host antiviral defense; however, their roles in bandavirus infection remain elusive. Here, we identify over 200 ISGs potentially inhibiting or promoting bandaviral replication. With SFTSV as the main model, we further systematically uncover the notable antiviral role of one ISG, cyclin D3 (CCND3), against bandaviruses. SFTSV infection induces CCND3 up-regulation and cytoplasmic translocation. CCND3, in turn, inhibits the viral replication in cultured cells and pathogenicity in vivo. The viral nucleoprotein (NP) is the target of CCND3. By its CN domain, CCND3 interacts with NP’s “head” region in an RNA-independent manner, suppressing the ribonucleoprotein (RNP) replication machinery activity. Furthermore, consistent with interaction interface mapping and structural modeling analyses, the CCND3-NP interaction blocks NP multimerization, NP-RNA binding, and NP association with viral polymerase, that is, the NP activities essential to RNP construction and functioning. Conversely, the viral nonstructural protein, NSs, can partially antagonize CCND3 by attenuating its induction and promoting autophagic degradation. These findings provide new insights into bandavirus-host interactions and arms race, advancing the understanding of bandavirus infection and probably informing antiviral therapeutic development.
- 26 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessInterferon-stimulated gene screening identifies CCND3 as a host restriction factor against emerging high-pathogenic bandaviruses
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a representative high-pathogenic bandavirus (Bandavirus genus, Phenuiviridae family). Inducible expression of interferon-stimulated genes (ISGs) is the foundation of host antiviral defense; however, their roles in bandavirus infection remain elusive. Here, we identify over 200 ISGs potentially inhibiting or promoting bandaviral replication. With SFTSV as the main model, we further systematically uncover the notable antiviral role of one ISG, cyclin D3 (CCND3), against bandaviruses. SFTSV infection induces CCND3 up-regulation and cytoplasmic translocation. CCND3, in turn, inhibits the viral replication in cultured cells and pathogenicity in vivo. The viral nucleoprotein (NP) is the target of CCND3. By its CN domain, CCND3 interacts with NP’s “head” region in an RNA-independent manner, suppressing the ribonucleoprotein (RNP) replication machinery activity. Furthermore, consistent with interaction interface mapping and structural modeling analyses, the CCND3-NP interaction blocks NP multimerization, NP-RNA binding, and NP association with viral polymerase, that is, the NP activities essential to RNP construction and functioning. Conversely, the viral nonstructural protein, NSs, can partially antagonize CCND3 by attenuating its induction and promoting autophagic degradation. These findings provide new insights into bandavirus-host interactions and arms race, advancing the understanding of bandavirus infection and probably informing antiviral therapeutic development.
- Open Access
- 15 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging bunyavirus that causes severe viral hemorrhagic fever and thrombocytopenia syndrome with a fatality rate of up to 30%. No licensed vaccines or therapeutics are currently available for humans. Here, we develop seven monoclonal antibodies (mAbs) against SFTSV surface glycoprotein Gn. Mechanistic studies show that three neutralizing mAbs (S2A5, S1G3, and S1H7) block multiple steps during SFTSV infection, including viral attachment and membrane fusion, whereas another neutralizing mAb (B1G11) primarily inhibits the viral attachment step. Epitope binning and X-ray crystallographic analyses reveal four distinct antigenic sites on Gn, three of which have not previously been reported, corresponding to domain I, domain II, and spanning domain I and domain II. One of the most potent neutralizing mAbs, S2A5, binds to a conserved epitope on Gn domain I and broadly neutralizes infection of six SFTSV strains corresponding to genotypes A to F. A single dose treatment of S2A5 affords both pre- and post-exposure protection of mice against lethal SFTSV challenge without apparent weight loss. Our results support the importance of glycoprotein Gn for eliciting a robust humoral response and pave a path for developing prophylactic and therapeutic antibodies against SFTSV infection.
- 15 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessA broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging bunyavirus that causes severe viral hemorrhagic fever and thrombocytopenia syndrome with a fatality rate of up to 30%. No licensed vaccines or therapeutics are currently available for humans. Here, we develop seven monoclonal antibodies (mAbs) against SFTSV surface glycoprotein Gn. Mechanistic studies show that three neutralizing mAbs (S2A5, S1G3, and S1H7) block multiple steps during SFTSV infection, including viral attachment and membrane fusion, whereas another neutralizing mAb (B1G11) primarily inhibits the viral attachment step. Epitope binning and X-ray crystallographic analyses reveal four distinct antigenic sites on Gn, three of which have not previously been reported, corresponding to domain I, domain II, and spanning domain I and domain II. One of the most potent neutralizing mAbs, S2A5, binds to a conserved epitope on Gn domain I and broadly neutralizes infection of six SFTSV strains corresponding to genotypes A to F. A single dose treatment of S2A5 affords both pre- and post-exposure protection of mice against lethal SFTSV challenge without apparent weight loss. Our results support the importance of glycoprotein Gn for eliciting a robust humoral response and pave a path for developing prophylactic and therapeutic antibodies against SFTSV infection.
- Open Access
- 7 May 2024
- Published by Taylor & Francis in Virulence
- Vol. 15 (1) , 2348252
Pathogenesis and virulence of Heartland virus
Heartland virus (HRTV), an emerging tick-borne pathogenic bunyavirus, has been a concern since 2012, with an increasing incidence, expanding geographical distribution, and high pathogenicity in the United States. Infection from HRTV results in fever, thrombocytopenia, and leucopenia in humans, and in some cases, symptoms can progress to severe outcomes, including haemorrhagic disease, multi-organ failure, and even death. Currently, no vaccines or antiviral drugs are available for treatment of the HRTV disease. Moreover, little is known about HRTV-host interactions, viral replication mechanisms, pathogenesis and virulence, further hampering the development of vaccines and antiviral interventions. Here, we aimed to provide a brief review of HRTV epidemiology, molecular biology, pathogenesis and virulence on the basis of published article data to better understand this virus and provide clues for further study.
- 7 May 2024
- Published by Taylor & Francis in Virulence
- Vol. 15 (1) , 2348252
Open AccessPathogenesis and virulence of Heartland virus
Heartland virus (HRTV), an emerging tick-borne pathogenic bunyavirus, has been a concern since 2012, with an increasing incidence, expanding geographical distribution, and high pathogenicity in the United States. Infection from HRTV results in fever, thrombocytopenia, and leucopenia in humans, and in some cases, symptoms can progress to severe outcomes, including haemorrhagic disease, multi-organ failure, and even death. Currently, no vaccines or antiviral drugs are available for treatment of the HRTV disease. Moreover, little is known about HRTV-host interactions, viral replication mechanisms, pathogenesis and virulence, further hampering the development of vaccines and antiviral interventions. Here, we aimed to provide a brief review of HRTV epidemiology, molecular biology, pathogenesis and virulence on the basis of published article data to better understand this virus and provide clues for further study.
- 23 January 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (1) , e0156823
Host factor MxA restricts Dabie bandavirus infection by targeting the viral NP protein to inhibit NP-RdRp interaction and ribonucleoprotein activity
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high case mortality rates, which is caused by Dabie bandavirus (DBV), a novel pathogen also termed as SFTS virus (SFTSV). Currently, no specific therapeutic drugs or vaccines are available for SFTS. Myxovirus resistance protein A (MxA) has been shown to inhibit multiple viral pathogens; however, the role of MxA in DBV infection is unknown. Here, we demonstrated that DBV stimulates MxA expression which, in turn, restricts DBV infection. Mechanistic target analysis revealed that MxA specifically interacts with the viral nucleocapsid protein (NP) in a manner independent of RNA. Minigenome reporter assay showed that in agreement with its targeting of NP, MxA inhibits DBV ribonucleoprotein (RNP) activity. In detail, MxA interacts with the NP N-terminal and disrupts the interaction of NP with the viral RNA-dependent RNA polymerase (RdRp) but not NP multimerization, the critical activities of NP for RNP formation and function. Furthermore, MxA N-terminal domain was identified as the functional domain inhibiting DBV infection, and, consistently, then was shown to interact with NP and obstruct the NP-RdRp interaction. Additionally, threonine 103 within the N-terminal domain is important for MxA inhibition to DBV, and its mutation (T103A) attenuates MxA binding to NP and obstruction of the NP-RdRp interaction. This study uncovers MxA inhibition of DBV with a series of functional and mechanistical analyses, providing insights into the virus−host interactions and probably helping inform the development of antiviral agents in the future. IMPORTANCE: DBV/SFTSV is an emerging high-pathogenic virus. Since its first identification in China in 2009, cases of DBV infection have been reported in many other countries, posing a significant threat to public health. Uncovering the mechanisms of DBV-host interactions is necessary to understand the viral pathogenesis and host response and may advance the development of antiviral therapeutics. Here, we found that host factor MxA whose expression is induced by DBV restricts the virus infection. Mechanistically, MxA specifically interacts with the viral NP and blocks the NP-RdRp interaction, inhibiting the viral RNP activity. Further studies identified the key domain and amino acid residue required for MxA inhibition to DBV. Consistently, they were then shown to be important for MxA targeting of NP and obstruction of the NP-RdRp association. These findings unravel the restrictive role of MxA in DBV infection and the underlying mechanism, expanding our knowledge of the virus-host interactions.
- 23 January 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (1) , e0156823
Host factor MxA restricts Dabie bandavirus infection by targeting the viral NP protein to inhibit NP-RdRp interaction and ribonucleoprotein activity
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high case mortality rates, which is caused by Dabie bandavirus (DBV), a novel pathogen also termed as SFTS virus (SFTSV). Currently, no specific therapeutic drugs or vaccines are available for SFTS. Myxovirus resistance protein A (MxA) has been shown to inhibit multiple viral pathogens; however, the role of MxA in DBV infection is unknown. Here, we demonstrated that DBV stimulates MxA expression which, in turn, restricts DBV infection. Mechanistic target analysis revealed that MxA specifically interacts with the viral nucleocapsid protein (NP) in a manner independent of RNA. Minigenome reporter assay showed that in agreement with its targeting of NP, MxA inhibits DBV ribonucleoprotein (RNP) activity. In detail, MxA interacts with the NP N-terminal and disrupts the interaction of NP with the viral RNA-dependent RNA polymerase (RdRp) but not NP multimerization, the critical activities of NP for RNP formation and function. Furthermore, MxA N-terminal domain was identified as the functional domain inhibiting DBV infection, and, consistently, then was shown to interact with NP and obstruct the NP-RdRp interaction. Additionally, threonine 103 within the N-terminal domain is important for MxA inhibition to DBV, and its mutation (T103A) attenuates MxA binding to NP and obstruction of the NP-RdRp interaction. This study uncovers MxA inhibition of DBV with a series of functional and mechanistical analyses, providing insights into the virus−host interactions and probably helping inform the development of antiviral agents in the future. IMPORTANCE: DBV/SFTSV is an emerging high-pathogenic virus. Since its first identification in China in 2009, cases of DBV infection have been reported in many other countries, posing a significant threat to public health. Uncovering the mechanisms of DBV-host interactions is necessary to understand the viral pathogenesis and host response and may advance the development of antiviral therapeutics. Here, we found that host factor MxA whose expression is induced by DBV restricts the virus infection. Mechanistically, MxA specifically interacts with the viral NP and blocks the NP-RdRp interaction, inhibiting the viral RNP activity. Further studies identified the key domain and amino acid residue required for MxA inhibition to DBV. Consistently, they were then shown to be important for MxA targeting of NP and obstruction of the NP-RdRp association. These findings unravel the restrictive role of MxA in DBV infection and the underlying mechanism, expanding our knowledge of the virus-host interactions.
- 6 December 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (6) , 1319-1328
The Neutralizing Monoclonal Antibodies against SFTS Group Bandaviruses Suggest New Targets of Specific or Broad-Spectrum Antivirals
: Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) belong to the severe fever with thrombocytopenia syndrome/Heartland group of genus Bandavirus in the family Phenuiviridae of order Bunyavirales. Severe fever with thrombocytopenia syndrome virus and HRTV, identified from ticks from Asia and America, respectively, are important pathogens causing severe febrile diseases in humans. Guertu virus, closely related to these two viruses, is a potential pathogen, but no confirmed infection has been identified. So far, human-derived neutralizing monoclonal antibodies (mAbs) against SFTSV have been identified as having a great potential to be developed as antivirals; however, there is still a lack of neutralizing mAbs to GTV and HRTV. In this study, five neutralizing the mAbs against GTV and HRTV were obtained by hybridoma screening technology, four of which (14B4, 14D8, and 20D4 derived from GTV, and 27C8 derived from HRTV) showed cross reactivity and neutralization to all three viruses, and one derived from HRTV (10D6) neutralized HRTV specifically. The possible mechanisms of mAbs cross neutralization among the three viruses are discussed by analyzing their glycoprotein (GP) sequences and structures. Generating these neutralizing mAbs provides important antiviral candidates against GTV, HRTV, and SFTSV despite their differential activities, and their protective effect could be further evaluated in virus-infected mice. Their differential neutralizing efficiency and specificity further suggested that the three viruses share common mechanisms on the basis of GP functioning, and that HRTV poses a unique mechanism that differs from the other viruses. These findings shed light on developing broad-spectrum antiviral strategies against bandaviruses and promoting an understanding of the bandavirus infection process.
- 6 December 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (6) , 1319-1328
The Neutralizing Monoclonal Antibodies against SFTS Group Bandaviruses Suggest New Targets of Specific or Broad-Spectrum Antivirals
: Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) belong to the severe fever with thrombocytopenia syndrome/Heartland group of genus Bandavirus in the family Phenuiviridae of order Bunyavirales. Severe fever with thrombocytopenia syndrome virus and HRTV, identified from ticks from Asia and America, respectively, are important pathogens causing severe febrile diseases in humans. Guertu virus, closely related to these two viruses, is a potential pathogen, but no confirmed infection has been identified. So far, human-derived neutralizing monoclonal antibodies (mAbs) against SFTSV have been identified as having a great potential to be developed as antivirals; however, there is still a lack of neutralizing mAbs to GTV and HRTV. In this study, five neutralizing the mAbs against GTV and HRTV were obtained by hybridoma screening technology, four of which (14B4, 14D8, and 20D4 derived from GTV, and 27C8 derived from HRTV) showed cross reactivity and neutralization to all three viruses, and one derived from HRTV (10D6) neutralized HRTV specifically. The possible mechanisms of mAbs cross neutralization among the three viruses are discussed by analyzing their glycoprotein (GP) sequences and structures. Generating these neutralizing mAbs provides important antiviral candidates against GTV, HRTV, and SFTSV despite their differential activities, and their protective effect could be further evaluated in virus-infected mice. Their differential neutralizing efficiency and specificity further suggested that the three viruses share common mechanisms on the basis of GP functioning, and that HRTV poses a unique mechanism that differs from the other viruses. These findings shed light on developing broad-spectrum antiviral strategies against bandaviruses and promoting an understanding of the bandavirus infection process.
- Open Access
- 14 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Interactome profiling of Crimean-Congo hemorrhagic fever virus glycoproteins
Crimean-Congo hemorrhagic fever virus (CCHFV) is a biosafety level-4 pathogen requiring urgent research and development efforts. The glycoproteins of CCHFV, Gn and Gc, are considered to play multiple roles in the viral life cycle by interactions with host cells; however, these interactions remain largely unclear to date. Here, we analyzed the cellular interactomes of CCHFV glycoproteins and identified 45 host proteins as high-confidence Gn/Gc interactors. These host molecules are involved in multiple cellular biological processes potentially associated with the physiological actions of the viral glycoproteins. Then, we elucidated the role of a representative cellular protein, HAX1. HAX1 interacts with Gn by its C-terminus, while its N-terminal region leads to mitochondrial localization. By the strong interaction, HAX1 sequestrates Gn to mitochondria, thus depriving Gn of its normal Golgi localization that is required for functional glycoprotein-mediated progeny virion packaging. Consistently, the inhibitory activity of HAX1 against viral packaging and hence propagation was further elucidated in the contexts of pseudotyped and authentic CCHFV infections in cellular and animal models. Together, the findings provide a systematic CCHFV Gn/Gc-cell protein-protein interaction map, but also unravel a HAX1/mitochondrion-associated host antiviral mechanism, which may facilitate further studies on CCHFV biology and therapeutic approaches.
- 14 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Open AccessInteractome profiling of Crimean-Congo hemorrhagic fever virus glycoproteins
Crimean-Congo hemorrhagic fever virus (CCHFV) is a biosafety level-4 pathogen requiring urgent research and development efforts. The glycoproteins of CCHFV, Gn and Gc, are considered to play multiple roles in the viral life cycle by interactions with host cells; however, these interactions remain largely unclear to date. Here, we analyzed the cellular interactomes of CCHFV glycoproteins and identified 45 host proteins as high-confidence Gn/Gc interactors. These host molecules are involved in multiple cellular biological processes potentially associated with the physiological actions of the viral glycoproteins. Then, we elucidated the role of a representative cellular protein, HAX1. HAX1 interacts with Gn by its C-terminus, while its N-terminal region leads to mitochondrial localization. By the strong interaction, HAX1 sequestrates Gn to mitochondria, thus depriving Gn of its normal Golgi localization that is required for functional glycoprotein-mediated progeny virion packaging. Consistently, the inhibitory activity of HAX1 against viral packaging and hence propagation was further elucidated in the contexts of pseudotyped and authentic CCHFV infections in cellular and animal models. Together, the findings provide a systematic CCHFV Gn/Gc-cell protein-protein interaction map, but also unravel a HAX1/mitochondrion-associated host antiviral mechanism, which may facilitate further studies on CCHFV biology and therapeutic approaches.
- Open Access
- 15 March 2023
- Published by Springer Nature in Research Square
Interactome analysis of Crimean-Congo hemorrhagic fever virus glycoproteins reveals HAX1 as a host restriction factor against the virion packaging
Crimean-Congo hemorrhagic fever virus (CCHFV) is a biosafety level-4 and World Health Organization-recognized priority pathogen requiring urgent Research & Development attention. The glycoproteins of CCHFV, Gn and Gc, are considered to play multiple roles in the viral life cycle by interactions with host cells; however, these interactions remain largely unclear to date. Here, we analyzed the cellular interactomes of CCHFV glycoproteins by affinity purification-quantitative mass spectrometry and identified 45 host proteins as high-confidence Gn/Gc interactors. These host molecules are involved in transmembrane transport, metabolism, oxidative stress, protein folding and glycosylation, etc., in line with the potential physiological actions of the viral glycoproteins. As a proof of principle, we detailedly elucidated the role of an identified cellular protein, HAX1, and therefore uncovered an interesting host antiviral strategy. HAX1 interacts with Gn by its C-terminus, while its N-terminal region leads to mitochondrial localization. By the strong interaction, HAX1 sequestrates Gn to mitochondria, thus depriving Gn of its normal Golgi localization that is indispensable for functional glycoprotein-mediated progeny virion packaging. Consistently, the notable inhibitory activity of HAX1 against viral packaging and hence propagation was further elucidated in the contexts of pseudotyped and authentic CCHFV infections by series of loss/gain-of-function assays in cellular and animal infection models. Together, the findings not only provide a systematic CCHFV Gn/Gc-host protein-protein interaction map, but also unravel a novel cellular antiviral mechanism, which may facilitate further studies on CCHFV biology and therapeutic approaches.
- 15 March 2023
- Published by Springer Nature in Research Square
Open AccessInteractome analysis of Crimean-Congo hemorrhagic fever virus glycoproteins reveals HAX1 as a host restriction factor against the virion packaging
Crimean-Congo hemorrhagic fever virus (CCHFV) is a biosafety level-4 and World Health Organization-recognized priority pathogen requiring urgent Research & Development attention. The glycoproteins of CCHFV, Gn and Gc, are considered to play multiple roles in the viral life cycle by interactions with host cells; however, these interactions remain largely unclear to date. Here, we analyzed the cellular interactomes of CCHFV glycoproteins by affinity purification-quantitative mass spectrometry and identified 45 host proteins as high-confidence Gn/Gc interactors. These host molecules are involved in transmembrane transport, metabolism, oxidative stress, protein folding and glycosylation, etc., in line with the potential physiological actions of the viral glycoproteins. As a proof of principle, we detailedly elucidated the role of an identified cellular protein, HAX1, and therefore uncovered an interesting host antiviral strategy. HAX1 interacts with Gn by its C-terminus, while its N-terminal region leads to mitochondrial localization. By the strong interaction, HAX1 sequestrates Gn to mitochondria, thus depriving Gn of its normal Golgi localization that is indispensable for functional glycoprotein-mediated progeny virion packaging. Consistently, the notable inhibitory activity of HAX1 against viral packaging and hence propagation was further elucidated in the contexts of pseudotyped and authentic CCHFV infections by series of loss/gain-of-function assays in cellular and animal infection models. Together, the findings not only provide a systematic CCHFV Gn/Gc-host protein-protein interaction map, but also unravel a novel cellular antiviral mechanism, which may facilitate further studies on CCHFV biology and therapeutic approaches.
- Open Access
- 1 February 2023
- Published by KEAI Publishing in Virologica Sinica
- Vol. 38 (1) , 34-46
Transcriptome profiling highlights regulated biological processes and type III interferon antiviral responses upon Crimean-Congo hemorrhagic fever virus infection
Crimean-Congo hemorrhagic fever virus (CCHFV) is a biosafety level-4 (BSL-4) pathogen that causes Crimean-Congo hemorrhagic fever (CCHF) characterized by hemorrhagic manifestation, multiple organ failure and high mortality rate, posing great threat to public health. Despite the recently increasing research efforts on CCHFV, host cell responses associated with CCHFV infection remain to be further characterized. Here, to better understand the cellular response to CCHFV infection, we performed a transcriptomic analysis in human kidney HEK293 cells by high-throughput RNA sequencing (RNA-seq) technology. In total, 496 differentially expressed genes (DEGs), including 361 up-regulated and 135 down-regulated genes, were identified in CCHFV-infected cells. These regulated genes were mainly involved in host processes including defense response to virus, response to stress, regulation of viral process, immune response, metabolism, stimulus, apoptosis and protein catabolic process. Therein, a significant up-regulation of type III interferon (IFN) signaling pathway as well as endoplasmic reticulum (ER) stress response was especially remarkable. Subsequently, representative DEGs from these processes were well validated by RT-qPCR, confirming the RNA-seq results and the typical regulation of IFN responses and ER stress by CCHFV. Furthermore, we demonstrate that not only type I but also type III IFNs (even at low dosages) have substantial anti-CCHFV activities. Collectively, the data may provide new and comprehensive insights into the virus-host interactions and particularly highlights the potential role of type III IFNs in restricting CCHFV, which may help inform further mechanistic delineation of the viral infection and development of anti-CCHFV strategies.
- 1 February 2023
- Published by KEAI Publishing in Virologica Sinica
- Vol. 38 (1) , 34-46
Open AccessTranscriptome profiling highlights regulated biological processes and type III interferon antiviral responses upon Crimean-Congo hemorrhagic fever virus infection
Crimean-Congo hemorrhagic fever virus (CCHFV) is a biosafety level-4 (BSL-4) pathogen that causes Crimean-Congo hemorrhagic fever (CCHF) characterized by hemorrhagic manifestation, multiple organ failure and high mortality rate, posing great threat to public health. Despite the recently increasing research efforts on CCHFV, host cell responses associated with CCHFV infection remain to be further characterized. Here, to better understand the cellular response to CCHFV infection, we performed a transcriptomic analysis in human kidney HEK293 cells by high-throughput RNA sequencing (RNA-seq) technology. In total, 496 differentially expressed genes (DEGs), including 361 up-regulated and 135 down-regulated genes, were identified in CCHFV-infected cells. These regulated genes were mainly involved in host processes including defense response to virus, response to stress, regulation of viral process, immune response, metabolism, stimulus, apoptosis and protein catabolic process. Therein, a significant up-regulation of type III interferon (IFN) signaling pathway as well as endoplasmic reticulum (ER) stress response was especially remarkable. Subsequently, representative DEGs from these processes were well validated by RT-qPCR, confirming the RNA-seq results and the typical regulation of IFN responses and ER stress by CCHFV. Furthermore, we demonstrate that not only type I but also type III IFNs (even at low dosages) have substantial anti-CCHFV activities. Collectively, the data may provide new and comprehensive insights into the virus-host interactions and particularly highlights the potential role of type III IFNs in restricting CCHFV, which may help inform further mechanistic delineation of the viral infection and development of anti-CCHFV strategies.
- Open Access
- 11 January 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12, 797189
Animal Model of Severe Fever With Thrombocytopenia Syndrome Virus Infection
Severe fever with thrombocytopenia syndrome (SFTS), an emerging life-threatening infectious disease caused by SFTS bunyavirus (SFTSV; genus Bandavirus, family Phenuiviridae, order Bunyavirales), has been a significant medical problem. Currently, there are no licensed vaccines or specific therapeutic agents available and the viral pathogenesis remains largely unclear. Developing appropriate animal models capable of recapitulating SFTSV infection in humans is crucial for both the study of the viral pathogenic processes and the development of treatment and prevention strategies. Here, we review the current progress in animal models for SFTSV infection by summarizing susceptibility of various potential animal models to SFTSV challenge and the clinical manifestations and histopathological changes in these models. Together with exemplification of studies on SFTSV molecular mechanisms, vaccine candidates, and antiviral drugs, in which animal infection models are utilized, the strengths and limitations of the existing SFTSV animal models and some important directions for future research are also discussed. Further exploration and optimization of SFTSV animal models and the corresponding experimental methods will be undoubtedly valuable for elucidating the viral infection and pathogenesis and evaluating vaccines and antiviral therapies.
- 11 January 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12, 797189
Open AccessAnimal Model of Severe Fever With Thrombocytopenia Syndrome Virus Infection
Severe fever with thrombocytopenia syndrome (SFTS), an emerging life-threatening infectious disease caused by SFTS bunyavirus (SFTSV; genus Bandavirus, family Phenuiviridae, order Bunyavirales), has been a significant medical problem. Currently, there are no licensed vaccines or specific therapeutic agents available and the viral pathogenesis remains largely unclear. Developing appropriate animal models capable of recapitulating SFTSV infection in humans is crucial for both the study of the viral pathogenic processes and the development of treatment and prevention strategies. Here, we review the current progress in animal models for SFTSV infection by summarizing susceptibility of various potential animal models to SFTSV challenge and the clinical manifestations and histopathological changes in these models. Together with exemplification of studies on SFTSV molecular mechanisms, vaccine candidates, and antiviral drugs, in which animal infection models are utilized, the strengths and limitations of the existing SFTSV animal models and some important directions for future research are also discussed. Further exploration and optimization of SFTSV animal models and the corresponding experimental methods will be undoubtedly valuable for elucidating the viral infection and pathogenesis and evaluating vaccines and antiviral therapies.